Related Experiment Video
Updated: May 26, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
Published on: January 26, 2024
[Biotherapy of malignant peritoneal effusions in ovarian carcinoma]
Abstract:
Malignant peritoneal effusions often arise in patients with ovarian carcinoma. They are a hazardous complication of cancer. Systematic intraperitoneal chemotherapy is not necessarily followed by long-term remission and may even induce untoward side effects. Intraperitoneal interleukin-2 (IL-2) and IL-2/lymphokine-activated killers (LAK) biotherapy showed high efficacy in treatment of ovarian carcinoma patients suffering from peritoneal effusions. The objective effect was 80.1% and 82.6%, respectively. Our results suggest that intraperitoneal biotherapy may be extended to dealing with malignant peritoneal effusions in ovarian carcinoma.

